Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01711866 · ClinicalTrials.gov registry record · Phase 4
A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease
A Phase 4 study of Advanced Idiopathic Parkinson's Disease, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 87
- Enrollment target
- 20
- Study locations
NCT01711866: Completed Phase 4 study of Advanced Idiopathic Parkinson's Disease, sponsored by UCB Biosciences.
NCT01711866 is a Phase 4 study of Advanced Idiopathic Parkinson's Disease that has completed, run by UCB Biosciences. The registered enrollment target is 87 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01711866, a Phase 4 study of Advanced Idiopathic Parkinson's Disease, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 87 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety and feasibility of switching subjects with advanced Parkinson's Disease (PD) from Pramipexole or Ropinirole to Rotigotine and to assess the effects of Rotigotine on motor and non-motor symptoms of Parkinson's Disease in subjects switched from previous treatment with either Pramipexole or Ropinirole.
Primary Outcome
The CGI Item 4 was used to assess side effects. It ranges from 0 to 4 as follows: * 0 = Side effects not assessable * 1 = No side effects * 2 = Side effects do not significantly interfere with subject's functioning * 3 = Side effects significantly interfere with the subject's functioning * 4 = Side effects outweigh therapeutic efficacy.
Conditions Studied
Interventions
- DRUG Rotigotine
Study Locations (20)
Other
- 202 - Sarawak
- 401 - Singapore
- 403 - Singapore
- 101 - Busan
- 102 - Busan
- 108 - Daegu
- 109 - Daegu
- 105 - Gyeonggi-do
- 103 - Seoul
- 104 - Seoul
- 106 - Seoul
- 107 - Seoul
- 301 - Linkou District
- 304 - Taichung
Florida
- 506 - Atlantis
- 508 - Miami Springs
Alabama
- 505 - Anniston
Georgia
- 502 - Atlanta
Ohio
- 501 - Dayton
Oklahoma
- 509 - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-03 |
| Phase | Phase 4 |
What the finished NCT01711866 record still lists
NCT01711866 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Advanced Idiopathic Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which Rotigotine is the first listed.
NCT01711866 names 20 study sites across 6 states, led by Other, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT01711866 about?
NCT01711866 is a clinical study titled "A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease". The purpose of this study is to assess the safety and feasibility of switching subjects with advanced Parkinson's Disease (PD) from Pramipexole or Ropinirole to Rotigotine and to assess the effects of Rotigotine on motor and non-motor symptoms of Parkinson's Disease in subjects switched from previou...
What is the current status of trial NCT01711866?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 87 participants. The study started on 2012-09. Estimated completion is 2013-03.
What conditions does trial NCT01711866 study?
This clinical trial studies the following conditions: Advanced Idiopathic Parkinson's Disease.
What interventions are being tested in trial NCT01711866?
The interventions under investigation include: Rotigotine (DRUG).
Who is sponsoring clinical trial NCT01711866?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01711866 being conducted?
This trial has 20 study locations across Alabama, Florida, Georgia, Ohio, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01711866's enrollment target sits among peer trials
87 923rd of 2000 higher than 1,076 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia